These effects of CYP1B1 on obesity and glucose intolerance could be attributed to the role of CYP1B1 in metabolizing steroid hormones and lipids that modulate metabolism, and the accumulation and distribution of adipose tissues [120, 121], suggesting that inhibition of CYP1B1 could be a biomarker in the treatment of obesity and T2DM. The gene discussed is CYP1B1; the disease is obesity disorder.